Influence of acute and repeated interleukin-2 administration on spatial learning, locomotor activity, exploratory behaviors, and anxiety

Behavioral Neuroscience

Volumn 113, Issue 5, 1999, Pages 1030-1041

  Lacosta, Susan ^a   Anisman, Hymie ^a   Merali, Zul ^b  

^a CARLETON UNIVERSITY   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 2;

ANIMAL EXPERIMENT; ANXIETY; ARTICLE; BEHAVIOR; EXPLORATORY BEHAVIOR; LEARNING; LOCOMOTION; MALE; MAZE TEST; MOUSE; NONHUMAN; PERFORMANCE; STIMULUS RESPONSE; WORKING MEMORY;

EID: 0342545862     PISSN: 07357044     EISSN: None     Source Type: Journal    
DOI: 10.1037/0735-7044.113.5.1030     Document Type: Article

References (51)

1. 3H]dopamine in rat cultured mesencephalic cells. Journal of Neurochemistry, 61, 1284-1290.
2. Anisman, H., Kokkinidis, L., Borowski, T., & Merali, Z. (1997). Differential effects of interleukin (IL)-1, IL-2 and IL-6 on responding for rewarding lateral hypothalamic stimulation. Brain Research, 779, 177-187.
3. Anisman, H., Kokkinidis, L., & Merali, Z. (1996). Influence of interleukin-2 on responding for electrical brain stimulation from the hypothalamus. Brain Research, 731, 1-11.
4. Anisman, H., & Merali, Z. (in press). Anhedonic and anxiogenic effects of cytokine exposure. In R. Dantzer, E. E. Wollmann, & R. Yirmiya (Eds.), Cytokines, stress and depression. New York: Plenum Press.
5. Anisman, H., Ravindran, A. V., Griffiths, J., & Merali, Z. (1999). Endocrine and cytokine correlates of major depression and dysthymia with typical or atypical features. Molecular Psychiatry, 4, 182-188.
6. Araujo, B. M., Lapchak, P. A., Collier, B., & Quirion, R. (1989). Localization of interleukin-2 immunoreactivity and interleukin-2 receptors in the rat brain: Interaction with the cholinergic system. Brain Research, 498, 257-266.
7. Bignami, G., & Michalek, H. (1978). Cholinergic mechanisms and aversively motivated behaviors. In H. Anisman & G. Bignami (Eds.), Psychopharmacology of aversively motivated behavior (pp. 173-256). New York: Plenum Press.
8. Brebner, K., Hayley, S., Lacosta, S., Zacharko, R., Merali, Z., & Anisman, H. (1998). Synergistic actions of interleukin (IL)-1β, IL-6 and TNF-alpha: Central neurochemical, neuroendocrine and behavioral alterations. Society for Neuroscience Abstracts, 24, 2075.
9. Capuron, L., Ravaud, A., Radat, F., Dantzer, R., & Goodall, G. (1998). Affects of interleukin-2 and alpha-interferon cytokine immunotherapy on the mood and cognitive performance of cancer patients. Neuroimmunomodulation, 5, 9.
10. Caraceni, A., Martini, C., Belli, F., Mascheroni, L., Rivoltini, L., Arienti, F., & Cascinelli, N. (1992). Neuropsychological and neurophysiological assessment of the central effects of interleukin-2 administration. European Journal of Cancer, 29A, 1266-1269.
11. Connor, T. J., Song, C., Leonard, B. E., Merali, Z., & Anisman, H. (1998). Comparative effects of interleukin-1β, -2, -6, and tumor necrosis factor-α administration on some behavioral, neurochemical, endocrine and immune parameters. Neuroscience, 84, 923-933.
12. Dantzer, R., Bluthe, R. M., Auber, A., Goodall, G., Bret-Dibat, J.-L., Kent, S., Goujon, E., Laye, S., Parnet, P., & Kelley, K. W. (1996). Cytokine actions on behavior. In N. J. Rothwell (Ed.), Cytokines and the nervous system (pp. 117-144). London: Landes.
13. Denicoff, K. D., Rubinow, D. R., Papa, M. Z., Simpson, L., Seipp, L. A., Lotze, M. T., Chang, A. E., Rosenstein, D., & Rosenberg, S. A. (1987). The neuropsychiatric effects of treatment with interleukin-2 and lymphokine-activated killer cells. Annals of Internal Medicine, 107, 293-300.
14. Dunn, A. J. (1990). Interleukin-1 as a stimulator of hormone secretion. Progress in NeuroEndocrinImmunology, 3, 26-34.
15. Farrar, W. L., Kilian, P. L., Ruff, M. R., Hill, J. M., & Pert, C. B. (1987). Visualization and characterization of interleukin-1 receptors in brain. Journal of Immunology, 139, 459-463.
16. Ganguli, R., Brar, J. S., Chengappa, K. R., Deleo, M., Yang, Z. W., Shurin, G., & Rabin, B. (1995). Mitogen-stimulated interleukin-2 production in never-medicated first episode schizophrenics - The influence of age of onset and negative symptoms. Archives of General Psychiatry, 52, 668-672.
17. Gray, T. S. (1991). Amygdala: Role in autonomic and neuroendocrine responses to stress. In J. A. McCubbin, P. G. Kaufmann, & C. B. Nemeroff (Eds.), Stress, neuropeptides and systemic disease (pp. 37-53). New York: Academic Press.
18. Hanisch, U. W., Neuhaus, J., Rowe, W., van Rossum, D., Moller, T., Kettenmann, H., & Quirion, R. (1997). Neurotonic consequences of central long-term administration of interleukin-2 in rats. Neuroscience, 79, 799-818.
19. Hanisch, U. W., & Quirion, R. (1996). Interleukin-2 as a neuroregulatory cytokine. Brain Research Reviews, 21, 246-284.
20. Hanisch, U. W., Rowe, W., Sharma, S., Meaney, M. J., & Quirion, R. (1994). Hypothalamic-pituitary-adrenal activity during chronic central administration of interleukin-2. Endocrinology, 135, 2465-2472.
21. Hanisch, U. W., Seto, D., & Quirion, R. (1993). Modulation of hippocampal acetylcholine release: Potent central actions of interleukin-2. Journal of Neuroscience, 13, 3368-3374.
22. Heilig, M., Koob, G. F., Ekman, R., & Britton, K. T. (1994). Corticotropin releasing factor and neuropeptide Y: Role in emotional integration. Trends in Neuroscience, 17, 80-84.
23. Imura, H., Fukata, J-I., & Mori, T. (1991). Cytokines and endocrine function: An interaction between the immune and neuroendocrine systems. Clinical Endocrinology, 35, 107-115.
24. Karanth, S., & McCann, S. M. (1991). Anterior pituitary hormone control by interleukin 2. Proceedings of the National Academy of Sciences USA, 88, 2961-2965.
25. Katsuura, G., Gottschall, P. E., & Arimura, A. (1988). Identification of a high-affinity receptor for interleukin-1 beta in rat brain. Biochemical and Biophysical Research Communications, 156, 61-67.
26. Kokkinidis, L., & Anisman, H. (1980). Amphetamine models of paranoid schizophrenia models: An overview and elaboration of animal experimentations. Psychological Bulletin, 88, 551-579.
27. Lacosta, S., Merali, Z., & Anisman, H. (1995). Cytokine-induced endocrine, neurochemical and behavioral alterations. Society for Neuroscience Abstracts, 21, 1397.
28. Lacosta, S., Merali, Z., & Anisman, H. (1996). Behavioral, endocrine and central neurochemical alterations induced by Interleukin-1. Society for Neuroscience Abstracts, 22, 2058.
29. Lacosta, S., Merali, Z., & Anisman, H. (1998). Influence of interleukin-1 on exploratory behaviors, plasma ACTH and cortisol, and central biogenic amines in mice. Psychopharmacology, 137, 351-361.
30. Lacosta, S., Merali, Z., & Anisman, H. (1999). Behavioral and neurochemical consequences of lipopolysaccharide in mice: Anxiogenic-like effects. Brain Research, 818, 291-303.
31. Lapchak, P. A. (1992). A role for IL-2 in the regulation of striatal dopaminergic function. NeuroReport, 3, 165-168.
32. Lapchak, P. A., Araujo, D. M., Quirion, R., & Beaudet, A. (1991). Immunoautoradiographic localization of interleukin 2-like immunoreactivity and interleukin 2 receptors (Tac antigen-like immunoreactivity) in the rat brain. Neuroscience, 44, 173-184.
33. Licinio, J., Seibyl, J. P., Altemus, M., Charney, D. S., & Krystal, J. H. (1993). Elevated levels of interleukin-2 in neuroleptic-free schizophrenics. American Journal of Psychiatry, 150, 1408-1410.
34. Maes, M. (1995). Evidence for an immune response in major depression: A review and hypothesis. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 19, 11-38.
35. Maes, M., Meltzer, H. Y., Bosmans, E., Bergmans, R., Vandoolaeghe, E., Ranjan, R., & Desnyder, R. (1995). Increased plasma concentrations of interleukin-2 soluble interleukin-6, soluble interleukin-2 and transferrin receptor in major depression. Journal of Affective Disorders, 34, 301-309.
36. McAllister, C. G., van Kammen, D. P., Rehn, T. J., Miller, A. N., Gurklis, J., Kelley, M. E., Yao, J., & Peters, J. L. (1995). Increases in CSF levels of interleukin-2 in schizophrenia: Effects of recurrence of psychosis and medication status. American Journal of Psychiatry, 152, 1291-1297.
37. Merrill, J. E. (1990). Interleukin-2 effects in the central nervous system. Annals of the New York Academy of Sciences, 594, 188-199.
38. Meyers, C. A., & Valentine, A. D. (1995). Neurological and psychiatric adverse effects of immunological therapy. CNS Drugs, 3, 56-68.
39. Muller, N., & Ackenheil, M. (1998). Psychoneuroimmunology and the cytokine action in the CNS: Implications for psychiatric disorders. Progress in Neuropsychopharmacology & Biological Psychiatry, 22, 1-33.
40. Nistico, G. (1993). Communication among central nervous system, endocrine and immune systems: Interleukin-2. Progress in Neurobiology, 40, 463-575.
41. Nistico, G., & De Sarro, G. (1991). Is interleukin-2 a neuromodulator in the brain? Trends in Neuroscience, 14, 146-150.
42. Petitto, J. M., & Huang, Z. (1994). Molecular cloning of a partial cDNA of the interleukin-2 receptor-β in normal mouse brain: In situ localization in the hippocampus and expression by neuroblastoma cells. Brain Research, 650, 140-145.
43. Petitto, J. M., McCarthy, D. B., Rinker, C. M., Huang, Z., & Getty, T. (1997). Modulation of behavioral and neurochemical measures of forebrain clopamine function in mice by species-specific interleukin-2. Journal of Neuroimmunology, 73, 183-190.
44. Raber, J., & Bloom, F. E. (1994). IL-2 induces vasopressin release from the hypothalamus and the amygdala: Role of nitric oxide-mediated signaling. Journal of Neuroscience, 14, 6187-6195.
45. Raber, J., Koob, G. F., & Bloom, F. E. (1995). Interleukin-2 (IL-2) induces corticotropin-releasing factor (CRF) release from the amygdala and involves a nitric oxide-mediated signaling: Comparison with the hypothalamic response. Journal of Pharmacology and Experimental Therapeutics, 272, 815-824.
46. Rothwell, N. J. (1999). Cytokines - killers in the brain? Journal of Physiology, 514, 3-17.
47. Seto, D., Karr, S., & Quirion, R. (1997). Evidence for direct and indirect mechanisms in the potent modulatory action of interleukin-2 on the release of acetylcholine in rat hypocampal slices. British Journal of Pharmacology, 120, 1151-1157.
48. Song, C., Merali, Z., & Anisman, H. (1999). Variations of nucleus accumbens dopamine and serotonin following systemic interleukin-1, interleukin-2, or interleukin-6 treatment. Neuroscience, 88, 823-836.
49. Squire, L. R. (1992). Memory and the hippocampus: A synthesis from findings from rats, monkeys, and humans. Psychological Review, 99, 195-231.
50. Whishaw, I. Q. ( 1985). Formation of a place learning-set by the rat: A new paradigm for neurobehavioral studies. Physiology and Behavior, 35, 139-143.
51. Zalcman, S., Green-Johnson, J., Murray, L., Nance, D. M., Dyck, D., Anisman, H., & Greenberg, A. (1994). Cytokine-specific central monoamine alterations induced by interleukin (IL)-1, IL-2 and IL-6. Brain Research, 643, 40-99.